Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,225 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02917720 | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients(NAUT) | active not recruiting | Phase 2 | 75 | European LeukemiaNetNETWORK | 2 | Sep 22, 2025 | clinicaltrials |
| NCT05061420 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) | terminated | Phase 2 | 59 | SanofiINDUSTRY | 11 | Sep 22, 2025 |
| NCT03283384 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.(NEOLBC) | active not recruiting | Phase 2 | 100 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03820063 | Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study(TRAIN-3) | active not recruiting | Phase 2 | 462 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04258943 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 60 | Children's Oncology GroupNETWORK | 8 | Sep 18, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT04180215 | A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers | completed | Phase 1 / Phase 2 | 198 | Hookipa Biotech GmbHINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | completed | Phase 2 | 113 | Regeneron PharmaceuticalsINDUSTRY | 8 | Sep 8, 2025 | clinicaltrials |
| NCT05263245 | The Pharmacological Effects of Using Cabozantinib With a Light Breakfast(Skippy 1) | completed | Phase 2 | 12 | dr. Tom van der HulleOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT06784791 | Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)(NEOpredict-EGF) | recruiting | Phase 2 | 20 | University Hospital, EssenOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | completed | Phase 2 | 263 | Incyte CorporationINDUSTRY | 11 | Aug 14, 2025 | clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06262438 | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients(CHIP-AML22/Q) | recruiting | Phase 2 | 60 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03482362 | Vinorelbine in Advanced BRAF-like Colon Cancer(EORTC1616) | completed | Phase 2 | 1 | The Netherlands Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | active not recruiting | Phase 2 | 172 | ALX Oncology Inc.INDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT01979393 | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | completed | Phase 2 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Aug 1, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | active not recruiting | Phase 2 | 189 | ALX Oncology Inc.INDUSTRY | 9 | Aug 1, 2025 | clinicaltrials |
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 31, 2025 | clinicaltrials |
| NCT03535740 | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib(ALTA-2) | completed | Phase 2 | 103 | Ariad PharmaceuticalsINDUSTRY | 15 | Jul 31, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02234050 | Trabectedin for Recurrent Grade II/III Meningioma | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Jul 10, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06687876 | Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy(MEMENTO) | recruiting | Phase 2 | 14 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC(M13DAP) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC(M14LTK) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT06630624 | Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM(INJECTABL-II) | recruiting | Phase 1 / Phase 2 | 120 | M.R. MeijerinkOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT07038304 | The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)(OLYMPIAN) | recruiting | Phase 2 | 35 | University Medical Center GroningenOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01378975 | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 10 | Jun 25, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT06219018 | Effect of Honey For CIN II(HoneyForCINII) | recruiting | Phase 1 / Phase 2 | 60 | Zuyderland Medisch CentrumOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT03739710 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 175 | GlaxoSmithKlineINDUSTRY | 12 | Jun 15, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 6 | Jun 11, 2025 | clinicaltrials |
| NCT05513365 | Phase II Dutasteride in Combination With CAB vs CAB in SDC(DUCT) | recruiting | Phase 2 | 26 | Radboud University Medical CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials